Menu
Président actuel depuis décembre 2020
Pédiatre Oncologue à l’institut Curie depuis 2010
franck.bourdeaut@curie.fr
Le Dr Franck Bourdeaut est pédiatre oncologue, travaillant à l’Institut Curie depuis 2010. Après une formation clinique, Franck Bourdeaut a réalisé une thèse dans le laboratoire d’Olivier Delattre consacrée aux liens entre le développement normal du système nerveux sympathique et le neuroblastome.
Son travail a en particulier contribué à identifier les premiers facteurs de prédisposition génétique au neuroblastome. Il a par la suite continué de porter un intérêt aux facteurs de prédisposition génétique aux cancers de l’enfant, en particulier pour les neuroblastomes et les tumeurs rhabdoïdes ; ces travaux l’ont amené à initier, avec le Dr Laurence Brugières de Gustave Roussy, le groupe de travail national, et désormais européen, consacrée aux prédispositions génétiques aux cancers de l’enfant.
Depuis 2012, il co-dirige avec le Dr Schleiermacher, l’équipe de Recherche Translationnelle en Oncologie pédiatriquie, au sein de l’unité INSRM U830 dirigée par le Dr olivier Delattre ; son travail de recherche en laboratoire actuellement porte sur les tumeurs embryonnaires du cerveau, en particulier les tumeurs rhabdoïdes et les médullobastomes. Le Dr Franck Bourdeaut est membre du conseil scientifique de la SFCE depuis 2015.
Les membres du conseil scientifique
Onco-pédiatre et médecin des CLCC depuis 1992 dans le département de cancérologie de l’enfant et de l’adolescent de Gustave Roussy.
Initialement en charge de l’unité de greffe du département je suis le chef du département depuis 2008.
Je suis membre du comité de direction de Gustave Roussy depuis février 2020.
J’ai travaillé principalement sur les protocoles de chimiothérapie à hautes doses dans les tumeurs de haut risque et sur les protocoles des Neuroblastomes de Haut risque pour lesquels je suis la coordinatrice au niveau européen de 2 protocoles européens (HR NBL2 et VERITAS).
Très impliquée dans le fonctionnement de la SFCE, j’ai été notamment présidente de son conseil scientifique de 2015 à 2019.
Je suis représentante de la SFCE dans le collectif GRAVIR
Je suis membre fondateur du groupe européen des neuroblastomes SIOPEN et en ai été présidente de 2013 à 2019, je suis maintenant dans l’advisory board
Complètement hors sujet , j’ai créé le comité d’éthique de Gustave Roussy en 2011 et en ai été présidente pendant les 3 premières années .
Mildred V. Strouss Professor of Translational Oncology University of California San Francisco
Dr. Katherine Matthay is internationally known for her work in advancing therapy of neuroblastoma. She served as North American continental president for the International Society of Pediatric Oncology, and as president of the Advances in Neuroblastoma Research Association.
She has chaired the neuroblastoma committee in the Children’s Oncology Group (COG) and currently continues to serve as senior advisor. She initiated several landmark randomized trials in neuroblastoma in the COG, improving outcome with high dose therapy and bone marrow transplant and with isotretinoin and then with antibody therapies.
Since 2012, she has led a weekly neuroblastoma on-line tumor board, Global Neuroblastoma Network, to advance the care of neuroblastoma in low and middle income countries. She established the NCI-funded NANT clinical trials consortium for targeted therapy of neuroblastoma, now in its 21st year. She has been a leader in the development of targeted radiotherapy for neuroblastoma with the 131I-mIBG, which she initiated at UCSF in 1987.
She cares for children with relapsed and resistant neuroblastoma from many corners of the world, providing new therapies to try to overcome tumor resistance.
Dominique Plantaz MD, PhD University Hospital Centre of Grenoble-Alps University of Grenoble-Alps
Pr/Dr Dominique Plantaz has been involved in neuroblastoma cares and researches for thirty years.
He is internationally known for the different clinical and biological works. As member of the French Neuroblastoma Committee of the French Society for Pediatric Oncology, he was mainly involved in the field of particular aspects such as intra-spinal invasion diagnosis and treatment of this tumor, long term follow-up and congenital neuroblastomas.
Considering biological aspects of research, he performed in 1995 early studies using Comparative Genomic Hybridization (CGH) technique in San Francisco (UCSF) and Grenoble (University Joseph Fourier) laboratories; Further developments of CGH allowed this analysis to become a standard of biological characterization of neuroblastic proliferations in the routine practice, with still current utilization around the world.
As member of the SIOPEN group, he actively participated in the different trials and studies proposed for the different risk groups, particularly for high risk neuroblastomas (HRNBL trials); He was a member, for some years, of the Executive Committee of the SIOPEN group and he is still Principal Investigator in France for 2 international studies, the spinal cord invasion registry and the LINES supra-renal congenital masses (diagnosed antenatally or before the first three months of life).
He is still involved in care, leading the Pediatric Immuno-Hemato-Oncology Unit of Grenoble. He teaches Pediatrics and Pediatric Oncology. He is involved in the field of Pediatric Hemato-Oncology in Developing Countries such as Vietnam and Brazil and would be interested to bring his knowledges in Africa.
Didier Surdez studied pharmacy and graduated at the University of Basel (Switzerland).
He then moved to Ecole polytechnique fédérale de Lausanne, EPFL (Switzerland) and focused on the identification and characterization of hematopoietic and neural stem cells using murine transgenic models and obtained is PhD in 2007.
After a post-doc in Olivier Delattre laboratory at Institut Curie in Paris (France), he was appointed in 2014 as senior scientist in this laboratory. During this period, he has focused his research most on Ewing sarcoma aiming at deciphering biological processes driving oncogenesis through molecular, genetic, epigenetic and bioinformatics approaches.
He has highlighted key EWSR1-FLI1 targets (PRKCB), vulnerabilities (PARPi) and secondary alterations (STAG2) in this cancer. Since 2012, he is also actively involved in ancillary studies of EEC (EE2012, rEECur) and Combinair3 clinical trials with the aim of identifying predictive biomarkers in Ewing sarcoma.
In addition, he is currently developing several fundamental and translational research projects focusing on pediatric tumors. With the idea of developing most relevant models to address key questions around tumor heterogeneity, plasticity and to identify novel therapeutic strategies, he has established with his team a large collection of PDX models of pediatric solid tumors (including Ewing sarcoma, neuroblastoma, rhabdoid tumor, osteosarcoma and RMS PDX models).
In parallel, he is currently deciphering the function of STAG2 mutation in Ewing sarcoma and investigating more particularly how loss of STAG2 affects the three-dimensional chromatin folding and participate to Ewing sarcoma oncogenesis.
As of march 2021, he was appointed assistant professor at the University of Zurich (Switzerland) and his laboratory will continue to focus on basic and translational research to fight against pediatric tumors.
Manager of the transfer Research for the neuroblastoma in Centre Léon Bérard, Lyon-France
Neuroblastoma is a biologically very heterogeneous tumor with a clinical manifestation ranging from spontaneous regression to highly aggressive metastatic disease.
The activities of our team focusses on the molecular characterization of neuroblastoma specific genetic alterations by analyzing tumor, metastatic samples and circulating tumor DNA (ctDNA) in the cell free DNA (cfDNA) extracted from plasma.
Our team has demonstrated the feasibility of the study of ctDNA and shown ctDNA may overcome issues of tumor heterogeneity and detect rare mutations which might not be identified by studying a single site of disease.
Moreover, the analysis of ctDNA at different steps of the disease is also used to assess of residual disease and the clonal evolution during the treatment.
Le conseil scientifique
Présentation du Dr Jean Michon
Dr Jean Michon, Ex-Président de la Société Française du Cancer de l’Enfant SFCE et fondateur du comité scientifique « l’association Hubert Gouin – Enfance & Cancer » en 2004.
Président jusqu’en 2020.
Droit exclusif Myriam Dupouy